


        Clinical Trials Appendix
      

        Q4 2022 Results Update
      




          Upcoming pipeline catalysts: 2023 and 2024
        

Oncology BioPharmaceuticals Rare Disease





                H1 2023
              



                H2 2023
              



                2024
              







            Regulatory decision
          



Imfinzi + Imjudo - hepatocellular carcinoma (1L) (HIMALAYA) (EU) Imfinzi +/- Imjudo - NSCLC (1L) (POSEIDON) (EU)
          

Lynparza - prostate cancer (1L) (PROpel) (US, JP)
          

Enhertu - HER2+ breast cancer (2L) (DESTINY-Breast03) (CN) Enhertu - HER2-low breast cancer (3L) (DESTINY-Breast04) (JP) Farxiga - HFpEF (DELIVER) (US)
          

Beyfortus - respiratory syncytial virus (US) Ultomiris - NMOSD (CHAMPION-NMOSD)
          



Enhertu - HER2m NSCLC (2L+) (DESTINY-Lung01) (EU, JP) Enhertu - HER2-low breast cancer (3L) (DESTINY-Breast04) (CN) Calquence - CLL (ASCEND) (CN)
          

Forxiga - HFpEF (DELIVER) (CN) Soliris - gMG (CN)
          

Soliris - NMOSD (CN)
          

Koselugo - NF1-PN (SPRINT) (CN)
          





            Regulatory submission and/or acceptance
          



Lynparza - gBRCA breast cancer (adjuvant) (OlympiA) (CN) Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02)capivasertib - HR+/HER2- breast cancer (1L) (CAPItello-291)Dato-DXd - NSCLC (3L) (TROPION-Lung01)
          

eplontersen - hATTR-PN(NEURO-TTRansform) (US) Beyfortus - respiratory syncytial virus (JP, CN) Evusheld - COVID-19 (TACKLE/PROVENT) (CN) danicopan - PNH with extravascular haemolysis
          



Tagrisso - EGFRm NSCLC (1L) (FLAURA2)
          

Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA) Imfinzi - NSCLC (neoadjuvant) (AEGEAN)
          

Imfinzi - liver cancer (adjuvant) (EMERALD-2)Imfinzi - bladder cancer (muscle invasive) (NIAGARA) Imfinzi - biliary tract cancer (TOPAZ-1) (CN)
          

Imfinzi - bladder cancer (1L) (NILE)
          

capivasertib - TNBC (locally adv./met.) (CAPItello-290)AZD3152 - prevention of COVID-19 (SUPERNOVA) ALXN1840 - Wilson disease
          






Tagrisso - EGFRm NSCLC (resectable, Stg. II/III) (NeoADAURA)
                



Calquence - MCL (1L) (ECHO)
                





Imfinzi + Imjudo - hepatocellular carcinoma (1L) (HIMALAYA) (CN)
                



camizestrant - HR+/HER2-neg breast cancer (SERENA-6)
                





Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2)
                



roxadustat - anaemia of myelodysplastic syndrome)
                





Imfinzi - liver cancer (locoregional) (EMERALD-1)
                



tozorakimab - acute respiratory failure (TILIA)
                





Imfinzi - SCLC (limited-stage) (ADRIATIC)
                



Breztri - severe asthma (KALOS)
                





Lynparza - ovarian cancer (1L) (DUO-O)
                



Breztri - severe asthma (LOGOS)
                





Lynparza - endometrial cancer (1L) (DUO-E)
                



Fasenra - bullous pemphigoid (FJORD)
                





Lynparza - prostate cancer (1L) (PROpel) (CN)
                



Fasenra - EGPA (MANDARA)
                





Enhertu - HER2+/HER2low gastric 3L (DESTINY-Gastric01) (CN)
                



Fasenra - HES (NATRON)
                





Enhertu - HER2+ gastric (2L) (DESTINY-Gastric04)
                



acoramidis - ATTR-CM(ALXN2060-TAC-302)
                





Enhertu - HER2-low breast cancer (2L) (DESTINY-Breast06)
                



anselamimab - AL amyloidosis (CAEL101-302)
                





Enhertu - High-risk HER2+ early breast cancer (non-met.)
                







                  (DESTINY-Breast11)
                










            Key Phase III data readouts
          






Tagrisso - EGFRm NSCLC (1L) (FLAURA2)




Tagrisso - EGFRm NSCLC (unresectable Stg. III) (LAURA)




Tagrisso - EGFRm NSCLC (resectable, Stg. II/III) (NeoADAURA)




                  Fasenra - CRwNP (ORCHID)






Imfinzi - NSCLC (neoadjuvant) (AEGEAN)




Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2)




Lynparza - PARP 1L BRCAwt ovarian cancer (MONO-OLA1)




Fasenra - bullous pemphigoid (FJORD)






Lynparza - ovarian cancer (1L) (DUO-O)




Imfinzi - SCLC (limited-stage)(ADRIATIC)




Enhertu - High-risk HER2+ early breast cancer (non-met.)
                



Saphnelo - moderate to severe SLE (TULIP-SC)






Dato-DXd - NSCLC (3L) (TROPION-Lung01)




Imfinzi - liver cancer (locoregional) (EMERALD-1)




                  (DESTINY-Breast11)
                



Tezspire - chronic rhinosinusitis with nasal polyps
                





roxadustat - anaemia of myelodysplastic syndrome
                



Imfinzi - liver cancer (adjuvant) (EMERALD-2)




Enhertu - HER2+ gastric (2L) (DESTINY-Gastric04)




                  (WAYPOINT)
                







Imfinzi - bladder cancer (muscle invasive) (NIAGARA)




Calquence - MCL (1L) (ECHO)




Tezspire - severe asthma (DIRECTION)








Imfinzi - bladder cancer (1L) (NILE)




Orpathys - NSCLC with MET exon 14 mutations (locally adv./met.)
                



Ultomiris - HSCT-TMA (ALXN1210-TM-313)








Lynparza - endometrial cancer (1L) (DUO-E)




camizestrant - HR+/HER2- breast cancer (SERENA-6)




Ultomiris - paedeatric HSCT-TMA(ALXN1210-TM-314)








Enhertu - HER2-low breast cancer (2L) (DESTINY-Breast06)




Dato-DXd - TNBC (locally recurrent inop./met.)
                



                  Koselugo - NF1-PN (KOMET)








capivasertib - TNBC (locally adv./met.) (CAPItello-290)




                  (TROPION-Breast02)
                



acoramidis - ATTR-CM (ALXN2060-TAC-302)








Farxiga - myocardial infarction (DAPA-MI)




tozorakimab - acute respiratory failure (TILIA)




anselamimab - AL amyloidosis (CAEL101-302)








Fasenra - EGPA (MANDARA)




Breztri - severe asthma (KALOS)










                  Fasenra - HES (NATRON)




Breztri - severe asthma (LOGOS)










AZD3152 - prevention of COVID-19(SUPERNOVA)












          2
        



          Appendix: Glossary.
        





          Clinical Trials Appendix: selected highlights
        




            Approved medicines: key LCM
          

            Next-wave pipeline
          






                  BioPharmaceuticals
                



                  Oncology
                



                  Rare Disease
                









                  Dato-DXd (TROP2 ADC)
                





                  tozorakimab (IL-33)
                









                  volrustomig (PD-1/CTLA-4)
                





                  AZD3152 (COVID-19 LAAB)
                



                  vemircopan (oral Factor D)
                







                  capivasertib (AKT)
                





                  eplontersen (LICA)
                



                  gefurulimab (C5 mini-body)
                







                  camizestrant (ngSERD)
                





                  mitiperstat (MPO)
                



                  ALXN1850 (ngHPP)
                







                  rilvegostomig (PD-1/TIGIT)
                





                  cotadutide (GLP-1/glucagon)
                









                  AZD5305 (PARP-1sel)
                







          3
        



          Appendix: Glossary.
        





          Movements since Q3 2022 update
        




                New to Phase I
              



                New to Phase II
              



                New to Pivotal trial
              



                New to registration
              





                NME
              



                NME
              



                NME
              







                AZD0186#




                MEDI1341#




                AZD3152¶








                GLP-1R agonism type-2 diabetes
              



                alpha synuclein mAb multiple system
              



                SARS-CoV-2 LAAB prevention of COVID-19
              









                atrophy/Parkinson's disease
              









                AZD6793
              





                ceralasertib + Imfinzi LATIFY#








                IRAK4 inhibitor inflammatory diseases
              



                rilvegostomig (AZD2936) ARTEMIDE-1#




                ATR inhibitor + PDL-1 mAb non-small cell lung
              









                PD-1/TIGIT bispecific mAb solid tumours
              



                cancer
              







                AZD9592
              











                EGFR/cMET solid tumours
              



                Additional indication
              



                gefurulimab
              









                mitiperstat#




                humanised bispecific VHH antibody generalised
              









                myeloperoxidase COPD
              



                myasthenia gravis
              









                mitiperstat#




                Additional indication
              









                myeloperoxidase NASH
              



                tozorakimab
              











                IL-33 mAb acute respiratory failure
              











                datopotamab deructucan AVANZAR#












                TROP2 ADC 1L NSCLC, squamous and non-
              











                squamous 1L NSCLC, TROP2 BM+
              











                Dato-DXd TROPION Lung07#












                TROP2 ADC 1L NSCLC PD-L1 <50% non-squamous
              











                Dato-DXdTROPION-Breast03#












                TROP2 ADC adjuvant residual disease triple
              











                negative breast cancer
              


















          Phase progressions based on first patient dose achievement.
        

4 #Partnered and/or in collaboration ¶Registrational Phase I/III trial Appendix: Glossary.
        





          Movements since Q3 2022 update
        




                Removed from Phase I
              



                Removed from Phase II
              



                Removed from Phase III
              



                Removed from registration
              















                NME
              



                NME
              



                Life-cycle management
              



                NME
              





                AZD8701 +/- Imfinzi#




                navafenterol#




                Fasenra HUDSON




                Airsupra (PT027)#2






                FOXP3 +/- PD-L1 mAb solid tumours
              



                MABA chronic obstructive pulmonary
              



                IL-5R mAb eosinophilic gastritis and
              



                ICS/SABA asthma
              







                disease
              



                eosinophilic gastroenteritis
              







                MEDI9253
              







                Life-cycle management
              





                rNDV IL-12 solid tumours
              



                Additional indication
              



                Imfinzi PEARL#




                Farxiga/Forxiga DELIVER2








                tozorakimab
              



                PD-L1 mAb 1st-line metastatic non-small cell
              



                SGLT2 inhibitor worsening HF or CV death in
              







                IL-33 mAb atopic dermatitis
              



                lung cancer
              



                patients with chronic heart failure
              







                Life-cycle management
              





Imfinzi +/- Imjudo + CTx POSEIDON#2








                Fasenra ARROYO






                PD-L1 mAb +/- CTLA-4 mAb + CTx 1st-line non-
              







                IL-5R mAb chronic spontaneous urticaria
              





                small cell lung cancer
              











Lynparza + abiraterone PROpel#2












                PARP inhibitor + NHA prostate cancer
              
















          Phase progressions based on first patient dose achievement.
        

5 2Approved #Partnered and/or in collaboration Appendix: Glossary.
        

This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments


            Original Link
          

            Original Document
          

            Permalink
          



Disclaimer
AstraZeneca plc published this content on 09 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2023 07:12:40 UTC.
      

